Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| AIM | 8-K | neutral | 3/10 | AIM ImmunoTech filed an 8-K furnishing a sponsored article by CEO Thomas Equels in Breaking Defense, promoting Ampligen | Aug 11, 2026 |
| VOR | PRESS-RELEASE | neutral | 3/10 | Vor Bio reported Q2 2026 financial results with net loss of $62.8M, cash of $466.1M (plus $48.4M from July ATM sales), a | Aug 11, 2026 |
| BNTX | INST-CLUSTER | mixed | 5/10 | BioNTech's 2026-Q2 institutional cluster shows a mixed picture: 5 buyers (led by a new $39.4M position from Assenagon As | Aug 11, 2026 |
| TBPH | PREM14A | bullish | 7/10 | Theravance Biopharma (TBPH) filed a preliminary proxy statement (PREM14A) for an extraordinary general meeting to approv | Aug 11, 2026 |
| IXHL | 8-K | bullish | 5/10 | Incannex Healthcare announced receipt of the final A$5.1 million (~$3.4M USD) R&D tax incentive refund from the Australi | Aug 11, 2026 |
| MREO | PRESS-RELEASE | neutral | 4/10 | Mereo BioPharma reported Q2 2026 results with zero revenue and a net loss of $7.0M, in line with consensus EPS of -$0.01 | Aug 11, 2026 |
| LEGN | 6-K | bullish | 7/10 | Legend Biotech reported Q2 2026 results showing a major inflection point: the company achieved its first-ever quarterly | Aug 11, 2026 |
| MANE | 8-K | neutral | 5/10 | Veradermics reported Q2 2026 net loss of $23.5M, widening from a $15.6M loss in Q2 2025, with no revenue and increasing | Aug 11, 2026 |
| TOVX | 8-K | neutral | 4/10 | Theriva Biologics reported Q2 2026 financial results with a net loss of $3.2M ($0.07/share), compared to a $13.1M loss ( | Aug 11, 2026 |
| MREO | 8-K | bullish | 6/10 | Mereo BioPharma entered into an option and license agreement with Sentynl Therapeutics (a Zydus Lifesciences subsidiary) | Aug 11, 2026 |
| SGMT | PRESS-RELEASE | neutral | 5/10 | Sagimet Biosciences reported Q2 2026 net loss of $14.0 million ($0.26 per share), wider than the $10.4 million loss in Q | Aug 11, 2026 |
| BCAX | PRESS-RELEASE | mixed | 6/10 | Bicara Therapeutics reported Q2 2026 results with a net loss of $0.82 per share, slightly better than the $0.83 consensu | Aug 11, 2026 |
| TARA | PRESS-RELEASE | neutral | 4/10 | Protara Therapeutics reported Q2 2026 net loss of $21.7M ($0.36/share), widening from a $15.0M loss in Q2 2025, driven b | Aug 11, 2026 |
| KLRS | PRESS-RELEASE | neutral | 4/10 | Kalaris Therapeutics reported Q2 2026 EPS of -$0.48, a 7.1% beat vs consensus of -$0.49, but net loss widened slightly t | Aug 11, 2026 |
| TOVX | PRESS-RELEASE | neutral | 5/10 | Theriva Biologics reported Q2 2026 financial results with a net loss of $3.2M ($0.07 per share) vs $13.1M ($1.93 per sha | Aug 11, 2026 |
| LBRX | PRESS-RELEASE | bullish | 7/10 | LB Pharmaceuticals reported Q2 2026 net loss of $51.6M ($1.71/share) vs $4.9M a year ago, reflecting heavy R&D investmen | Aug 11, 2026 |
| NGNE | 8-K | bullish | 7/10 | Neurogene reported Q2 2026 financial results, highlighting continued positive Phase 1/2 data for NGN-401 in Rett syndrom | Aug 11, 2026 |
| AUTL | 8-K | bullish | 7/10 | Autolus Therapeutics reported Q2 2026 AUCATZYL net product revenue of $45.7M, up 119% YoY, and raised FY 2026 guidance t | Aug 11, 2026 |
| SGMT | 8-K | mixed | 5/10 | Sagimet Biosciences reported Q2 2026 financial results, highlighting a net loss of $13.95 million ($0.26 per share) vers | Aug 11, 2026 |
| ZURA | 8-K | bullish | 6/10 | Zura Bio reported Q2 2026 financial results with a net loss of $26.3M ($0.21/share), wider than the $16.0M loss in Q2 20 | Aug 11, 2026 |
| BCAX | 8-K | mixed | 6/10 | Bicara Therapeutics reported Q2 2026 results with a net loss of $0.82 per share, slightly better than the $0.83 consensu | Aug 11, 2026 |
| INTS | 8-K | neutral | 5/10 | Intensity Therapeutics reported Q2 2026 results with a net loss of $3.0M, wider than the $2.5M loss in Q2 2025, and cash | Aug 11, 2026 |
| PRLD | 8-K | neutral | 4/10 | Prelude Therapeutics reported Q2 2026 results with a net loss of $13.9M ($0.14/share), narrower than the $31.2M loss in | Aug 11, 2026 |
| IMNN | 8-K | neutral | 5/10 | Imunon reported Q2 2026 net loss of $2.8M ($0.54/share), slightly wider than the $2.7M loss in Q2 2025, with operating e | Aug 11, 2026 |
| COYA | 8-K | neutral | 4/10 | Coya Therapeutics reported Q2 2026 financial results with a net loss of $6.6M ($-0.28/share) vs $6.1M ($-0.36/share) in | Aug 11, 2026 |
| KLRS | 8-K | neutral | 4/10 | Kalaris Therapeutics reported Q2 2026 results with a net loss of $11.5M ($-0.48/share), slightly wider than the $11.4M l | Aug 11, 2026 |
| TARA | 8-K | neutral | 4/10 | Protara Therapeutics reported Q2 2026 results with a net loss of $21.7M ($0.36/share), widening from a $15.0M loss in Q2 | Aug 11, 2026 |
| LBRX | 8-K | bullish | 7/10 | LB Pharmaceuticals reported Q2 2026 financial results, with net loss of $51.6M ($1.71/share) vs $4.9M ($13.58/share) a y | Aug 11, 2026 |
| AURA | PRESS-RELEASE | bearish | 6/10 | Aura Biosciences reported Q2 2026 EPS of -$0.48, a 33.3% miss vs consensus of -$0.38, with revenue of $0. The net loss w | Aug 11, 2026 |
| CALC | PRESS-RELEASE | neutral | 4/10 | CalciMedica reported Q2 2026 financial results with a net loss of $7.7M ($0.45/share) vs $6.0M ($0.40/share) in Q2 2025, | Aug 11, 2026 |